Comparative Pharmacology
Head-to-head clinical analysis: MAXIDEX versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIDEX versus RAYOS.
MAXIDEX vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIDEX (dexamethasone) is a potent glucocorticoid that binds to the glucocorticoid receptor (GR), leading to modulation of gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes. It suppresses immune response through inhibition of cytokine production (e.g., IL-1, IL-2, TNF-alpha) and reduces vasodilation and vascular permeability.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
One to two drops of the 0.1% ophthalmic suspension into the conjunctival sac every hour during the day and every two hours at night initially; after improvement, reduce to one drop every four hours, then one drop three to four times daily.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for dexamethasone; in ocular tissues, half-life may be prolonged due to local retention, but systemic half-life is short with minimal accumulation.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for <15% unchanged drug; biliary/fecal elimination of metabolites predominates.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid
Corticosteroid